Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

The conversation is about using a Dr. Pen for microneedling on a widow's peak, with advice to use a depth of 1.25mm and hold it in place for 10 seconds. The user is also using minoxidil.

Mixing PGE2 and sandalwood oil for hair regrowth. Suggested formula: 1 drop sandalore to 30 ml carrier oil.

Procapil is claimed to be better than Minoxidil for hair loss. Users discuss the effectiveness of various treatments, including Minoxidil, Finasteride, RU58841, and The Ordinary's Multi Peptide Hair Serum.

The user shared progress pictures after using minoxidil twice daily, rosemary, pumpkin seed, and castor oil three times a week, and a derma roller once a week for two months. The conversation discusses the effectiveness of these treatments for hair loss.

The user uses a 1.5mm derma stamp weekly for hair loss and applies minoxidil afterward, feeling a slight burn but no bleeding. They question if bleeding, seen in others using a derma pen, indicates proper technique.

People are discussing making their own PP405 for hair loss treatment using JLX069 and DMSO. There is skepticism about the safety and effectiveness of this homemade solution, with some users expressing concerns about potential risks.

User wants to add RCP to regimen and asks if it can be applied with topical minoxidil and/or finasteride at night.

Minoxidil, dutasteride, and copper peptides are used in a tattooing method for hair regrowth, with some users noting better results compared to oral treatments. Copper peptides are considered to have minimal impact, but the method may reduce side effects.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

Minoxidil 5% combined with 0.01% tretinoin may be as effective as using minoxidil twice daily. Users discuss switching to oral minoxidil for consistency, with concerns about side effects.

The user experienced side effects from using 1% finasteride and 2% minoxidil, including dermatitis, erectile dysfunction, and heart palpitations. They switched to using 2000mg pumpkin seed oil, saw palmetto capsules, and applying pumpkin seed oil and rosemary oil twice a week, seeking feedback on results.

PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.

User discusses a promising topical Procyanidin B2 treatment for hair loss. Users share mixed experiences and mention effective treatments like finasteride, minoxidil, and LLLT.

A user shared progress photos showing hair regrowth using 5% minoxidil foam, microneedling, and 2% ketoconazole. They also started taking multivitamins and are considering adding finasteride.

The user is experiencing an allergic reaction to propylene glycol in Kirkland minoxidil and is considering switching to a foam version or a low-PG minoxidil solution. They are also contemplating oral minoxidil but are concerned about its long-term safety.

Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

Enhancing minoxidil effects can involve using penetration enhancers like DMSO, urea, or retinol, and methods like dermarolling and adding substances like biotin and L-carnitine tartrate. Some users suggest trying higher concentrations of minoxidil if lower percentages are ineffective.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

The user is seeking a topical minoxidil and finasteride combination without propylene glycol due to scalp irritation. They are looking for a supplier in the US.

RU58841 powder is mixed with a 70% ethanol and 30% propylene glycol solution, with some users seeking PG-free alternatives. Minoxidil is also mentioned as a treatment option.

The user is using a hair recovery treatment with 0.5 mg dutasteride, 5 mg biotin, 5% topical minoxidil, and dermarolling twice a week. They are considering using a 1.5 mm dermaroller and red light therapy.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

The user reported slight improvement in hairline using 1% Clascoterone cream over three months but found it too costly to continue. They expressed interest in trying a 5% concentration if it becomes available at a reasonable price.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

A user is considering using verteporfin with microneedling, oral/topical minoxidil, and RU58841 to treat hair loss. They seek advice on dosage and application methods.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.